Decision to cut drug for obesity criticised


ONE OF Ireland’s leading obesity experts has strongly criticised the HSE’s decision to cut its reimbursement of the only prescription weight-loss medication currently available in Ireland.

The HSE announced last week that it would no longer cover weight-loss drug Orlistat, as part of its package of cuts aimed at saving €130 million. Consultant endocrinologist at St Columcille’s Hospital, Loughlinstown, Prof Donal OShea, said the move discriminated against those who are obese.